Tango Therapeutics (TNGX): Paradigm Biocapital Advisors LP added to its stake +2.35M shares
Paradigm Biocapital Advisors LP added to its stake in Tango Therapeutics, per its Q2 2026 13F.
- 6.36M
- Shares reported · +2.35M vs prior quarter
- 3.7%
- Disclosed portfolio weight
- $199M
- Reported value
- Holdings as of
- Jun 30, 2026
- Filed
- Aug 14, 2026
What stands out in this filing
- 4,009,679 shares in Q1 2026, 6,357,523 now (+58.6% in share count).
- Reported at $199M, 3.72% of the portfolio value in this 13F filing.
- 9 other tracked managers reported the same kind of change for Q2 2026.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jun 19, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 19, 2026, the Board of Directors (the “Board”) of Tango Therapeutics, Inc. (the “Company”) increased the number of directors of the Company to seven (7).”
- Jul 31, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“Dr. Barbara Weber’s employment with Tango Therapeutics, Inc. (the “Company”) as its Executive Chair ended on August 3, 2026 in accordance with the terms of her Amended and Restated Employment Agreement dated January 8, 2026 (the “Employment Agreement”).”
- Jul 31, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On August 6, 2026, Dr. Weber and the Company executed the separation agreement (the “Separation Agreement”), which provides for Dr. Weber to receive: (i) severance pay at Dr. Weber’s current base salary through December 31, 2026, paid out in substantially equal installments, and (ii) reimbursement for any monthly COBRA premium payments up to December 31, 2026.”
- Aug 11, 2026Company filing · Form 8-K · ResultsReported its results
What came next
- Oct 1, 2026Insider · 1 personInsiders: 2 sales (~$661K)
- Nov 2, 2026Insider · 2 peopleInsiders: 4 sales (~$270K)
- Nov 6, 20265% stakeFMR LLC reported a passive stake (13G) of 15.0%
- Nov 9, 2026Company filing · Form 8-K · ResultsReported its results
- Nov 11, 2026InsiderOfficer sold ~$125K of TNGX shares in the open market
- Nov 16, 20265% stakeTCG Crossover GP II, LLC reported a passive stake (13G) of 4.6%
- Nov 16, 20265% stakeFarallon Capital Management, L.L.C. reported a passive stake (13G) of 4.9%
- Nov 17, 2026InsiderDirector sold ~$80K of TNGX shares in the open market
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Tango Therapeutics
For Tango Therapeutics, OQRO holds 10 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TNGX page.
How this filing works
Explore the data
Common questions
What does this filing report about Tango Therapeutics (TNGX) stock?
Paradigm Biocapital Advisors LP added to its stake in Tango Therapeutics, per its Q2 2026 13F. Now 6.36M shares, $199M reported value, 3.7% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Jun 30, 2026. Filed: Aug 14, 2026.
What stands out in this filing?
4,009,679 shares in Q1 2026, 6,357,523 now (+58.6% in share count). Reported at $199M, 3.72% of the portfolio value in this 13F filing. 9 other tracked managers reported the same kind of change for Q2 2026.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Tango Therapeutics recently?
For Tango Therapeutics, OQRO holds 10 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the TNGX page.
Does this mean TNGX stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Tango Therapeutics
- SEC Form 4Nov 19, 2026
- SEC Form 144Nov 17, 2026
- SEC Schedule 13GNov 16, 2026
- SEC Schedule 13GNov 16, 2026
- SEC Form 4Nov 13, 2026
- SEC Form 4Nov 5, 2026
Everything OQRO holds on this company is on its TNGX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
